Recombinant Biglycan (BGN) Homo sapiens (Human) Recombinant protein

DSPG1; PG-S1; PGI; SLRR1A; Biglycan Proteoglycan; Bone/cartilage proteoglycan I

Add to Cart Distributors
Overview
Properties
  • Source Prokaryotic expression, Host E.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted, extracellular space, extracellular matrix
  • Molecular Mass 17.3kDa, Accurate 17kDa(Analysis of differences refer to the manual)
  • Residues & TagsThr230~Tyr366 (Accession # P21810) with
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point7.9
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Recombinant Biglycan (BGN) Packages (Simulation)
  • Recombinant Biglycan (BGN) Packages (Simulation)
  • RPJ226Hu02.jpg SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in PBS or others.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysreCavia (Guinea pig )lation of biglycanPubmed:27295191
  • Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing.pubmed:29022912
  • Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valvePubmed: 30563371
  • Die Rolle der extrazellulären Matrix in der degenerativen Aortenklappenerkrankung unter dem Einfluss von Diabetes
  • Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans33407555
  • Inhibition of Stromal Biglycan Promotes Normalization of the Tumor Microenvironment and Enhances Chemotherapeutic Efficacy33966638

Recommend products